Vivos Inc.
(OTC: ADMD)

 Fact Sheet

Vivos Inc. (Advanced Medical Isotope) is a Kennewick, Washington-based late stage development company, engaged in the development of a brachytherapy device for the treatment of cancerous tumors. Brachytherapy uses radiation to destroy tumors by placing a radioactive isotope inside the treatment area. Currently, the company is pursuing FDA approval of its brachytherapy device, RadioGel, initially for the treatment of advanced basal and squamous skin cancers. Concurrently, the Company is pursuing development of veterinary applications for a range of cancers in collaboration with four leading university veterinary hospitals. Veterinary applications should have a faster path to revenue for ADMD, while providing data supporting the safety and therapeutic effectiveness of RadioGel. ADMD’s RadioGel requires no pre-market approval for pet therapy and the Company plans to generate near term revenue from veterinarian clinics and international licensing by 1Q18.

Find a broker to begin trading ADMD now

Company Name Vivos Inc.(Advanced Medical Isotope)
Market/Symbol OTC: ADMD
Recent Price
Market Cap $1.77M
Avg. Daily Vol. (3m) 225,836
Price/Book N/A
Price/Cash Flow N/A
As of Dec. 12, 2017
*Source: QuoteMedia


Begin trading ADMD

 Find Broker

SIGN UP FOR EMAIL ALERTS

BE THE FIRST TO RECEIVE BREAKING NEWS

Recent Company Videos


Vivos Inc. Presentation at RedChip's December 2017 Conference

Dec. 11, 2017

Visit https://www.redchip.com/events/14 to view the PowerPoint presentation. Vivos Inc. (Advanced Medical Isotope) is a Kennewick, Washington-based late stage development company, engaged in the development of a brachytherapy device for the treatment of cancerous tumors. Brachytherapy uses radiation to destroy tumors by placing a radioactive isotope…


Vivos Inc.(Advanced Medical Isotope) Latest News


Latest Investor Presentation

Latest Investor Presentation

 View Full Presentation |  Download

Ask the CEO



ADMD Research

The Company is pursuing development of veterinary applications for a range of cancers in collaboration with four leading university veterinary hospitals. Veterinary applications should… Read More

Aug. 21, 2017

For over two decades RedChip Companies has been writing research on small-cap stocks. RedChip was the first to put independent research coverage on Starbucks in 1992. Our research analysts, CFAs, include financial models and target prices based on industry competitors. Our analysts cover dozens of stocks with a focus on healthcare, technology, social media, and consumer goods.

RedChip Companies research reports are distributed to 60,000 opt-in retail, institutional, and accredited investors.

Receive ADMD Email Alerts

*By entering your information you agree to our privacy policy.


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market